India, March 27 -- AstraZeneca Pharma India has received permission to import for sale and distribution of Trastuzumab deruxtecan lyophilised powder for concentrate for solution for infusion 100mg from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India for two additional indications.

The new indications are:

HER2-Low Metastatic Breast Cancer:Trastuzumab deruxtecan is now indicated for the treatment of adult patients with unresectable or metastatic HER2-Low breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.

Locally Advanced or Metastatic Gastric Cance...